Omeprazole Xeolas Pharmaceuticals

Omeprazole, the active ingredient in Omeprazole Xeolas Pharmaceuticals, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to treat acid‑related disorders in adults and adolescents. GNH USA supplies Omeprazole Xeolas Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor indicated for several acid‑related conditions. - Gastroesophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Peptic ulcer disease: facilitates ulcer healing by suppressing gastric acid secretion. - NSAID‑induced gastric ulcer: protects the gastric mucosa in patients taking non‑steroidal anti‑inflammatory drugs. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens used to eradicate H. pylori. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools that may resolve with continued therapy. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of queasiness, often transient. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis requiring medical attention. - Anaphylaxis: life‑threatening allergic reaction with rash, swelling, or breathing difficulty. - Stevens‑Johnson syndrome: rare skin disorder with blistering and detachment. - Elevated liver enzymes: indication of hepatic stress. - Hypomagnesemia: low magnesium levels that may cause muscle cramps or arrhythmias. - Increased risk of bone fractures: especially with long‑term use.

Before initiating therapy, consider the following precautions. - Renal function assessment: adjust use in patients with severe renal impairment. - Hepatic disease evaluation: monitor liver function in patients with existing liver conditions. - Long‑term therapy monitoring: watch for potential bone density loss and magnesium deficiency. - Hypersensitivity check: avoid in individuals with known allergy to omeprazole or other PPIs. - Drug interaction review: assess concomitant medications that may alter omeprazole effectiveness. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several medicines.

Major Interactions (Avoid): - Clopidogrel: reduced conversion to its active metabolite, decreasing antiplatelet effect. - Atazanavir: decreased absorption leading to sub‑therapeutic antiviral levels. - HIV protease inhibitors (e.g., ritonavir): lowered plasma concentrations, compromising HIV control.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels may require dosage adjustment. - Phenytoin: reduced plasma concentration, potentially lowering seizure control. - Vitamin B12: decreased absorption with prolonged use, consider supplementation.